Handelsbanken Fonder AB Raises Position in Ascendis Pharma A/S (NASDAQ:ASND)

Handelsbanken Fonder AB boosted its position in Ascendis Pharma A/S (NASDAQ:ASND) by 31.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,667 shares of the biotechnology company’s stock after purchasing an additional 4,200 shares during the period. Handelsbanken Fonder AB’s holdings in Ascendis Pharma A/S were worth $2,638,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Profund Advisors LLC raised its position in shares of Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after purchasing an additional 85 shares during the period. GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 102 shares during the period. Rhumbline Advisers lifted its position in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 143 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Ascendis Pharma A/S by 1.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock valued at $2,064,000 after purchasing an additional 159 shares in the last quarter. Finally, Private Ocean LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter valued at $36,000.

Ascendis Pharma A/S Trading Down 2.1 %

Shares of Ascendis Pharma A/S stock opened at $129.30 on Thursday. The business’s 50-day moving average price is $135.42 and its 200-day moving average price is $136.11. The firm has a market capitalization of $7.53 billion, a PE ratio of -13.45 and a beta of 0.64. Ascendis Pharma A/S has a 12 month low of $85.29 and a 12 month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Ascendis Pharma A/S had a negative net margin of 154.18% and a negative return on equity of 16,574.15%. As a group, analysts predict that Ascendis Pharma A/S will post -7.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ASND shares. Citigroup raised their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. reduced their price objective on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, September 4th. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a report on Monday, September 16th. Finally, Jefferies Financial Group upped their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $195.00.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.